iRhythm Technologies, Inc. is a digital healthcare company that applies artificial intelligence and deep learning to cardiac diagnostics. Founded in 2006 and publicly listed on Nasdaq under the ticker IRTC, the company develops wearable cardiac monitoring solutions that capture continuous, high-quality ECG data to detect heart arrhythmias. Its machine-learning work sits at the centre of the product: FDA-cleared clinical algorithms analyse heartbeat data at scale, with accuracy clinically proven to be equivalent to that of expert cardiologists.
The company's technology stack spans deep learning and machine learning, ECG and cardiac signal analysis, wearable biosensors, and FDA-cleared clinical algorithms. Its flagship product, the Zio ECG monitor, is a single-use wearable patch that patients wear for up to 14 days to collect continuous ECG data. The accompanying iRhythm AI analysis platform processes this data using deep-learning technology combined with validated clinical algorithms.
The scale of the underlying data is substantial: iRhythm reports having served more than 8 million patients and analysed over 1.5 billion hours of heartbeat data. The company operates in the United States, the United Kingdom and Japan, working across healthcare, cardiology, medical devices and diagnostics, and remote patient monitoring. Its stated mission is 'to boldly innovate trusted solutions that detect, predict, and prevent disease', with an emphasis on patient-centric design and clinical validation.
